
## Massimo Geuna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5494762/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning. Cancers, 2020, 12, 1684.	3.7	25
2	Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells, 2020, 9, 2666.	4.1	11
3	Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study. Annals of Hematology, 2019, 98, 1083-1093.	1.8	8
4	Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. Immunotherapy, 2018, 10, 753-767.	2.0	0
5	Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. European Journal of Haematology, 2017, 99, 27-35.	2.2	10
6	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. Human Gene Therapy, 2015, 26, 220-231.	2.7	15
7	Cells Lacking the Fumarase Tumor Suppressor Are Protected from Apoptosis through a Hypoxia-Inducible Factor-Independent, AMPK-Dependent Mechanism. Molecular and Cellular Biology, 2012, 32, 3081-3094.	2.3	29
8	Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ Case Reports, 2012, 2012, bcr0220125797-bcr0220125797.	0.5	65
9	Macrogol hypersensitivity in multiple drug allergy. Annals of Allergy, Asthma and Immunology, 2011, 107, 542-543.	1.0	24
10	Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies. Cytotherapy, 2011, 13, 1140-1152.	0.7	8
11	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. European Journal of Haematology, 2011, 87, 409-418.	2.2	14
12	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. Immunology Letters, 2011, 134, 137-144.	2.5	17
13	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation, 2010, 120, 2858-2866.	8.2	309
14	Microenvironment drives the endothelial or neural fate of differentiating embryonic stem cells coexpressing neuropilinâ€1 and Flkâ€1. FASEB Journal, 2009, 23, 68-78.	0.5	17
15	T Cell Receptor (TCR) Gene Transfer with Lentiviral Vectors Allows Efficient Redirection of Tumor Specificity in Naive and Memory T Cells Without Prior Stimulation of Endogenous TCR. Human Gene Therapy, 2009, 20, 1576-1588.	2.7	34
16	IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival. Journal of Immunotherapy, 2009, 32, 920-931.	2.4	42
17	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20864-20869.	7.1	95
18	Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. International Immunology, 2008, 20, 841-848.	4.0	106

Massimo Geuna

#	Article	IF	CITATIONS
19	Alternative BCR/ABL Splice Variants in Philadelphia Chromosome–Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches. Cancer Research, 2007, 67, 5300-5307.	0.9	43
20	Ageâ€dependent accumulation of monoclonal CD4 <sup>+</sup> CD8 <sup>+</sup> double positive T lymphocytes in the peripheral blood of the elderly. British Journal of Haematology, 2007, 139, 780-790.	2.5	84
21	Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood, 2006, 107, 3795-3803.	1.4	46
22	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2005, 21, 207-218.	2.8	64
23	HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. Journal of Clinical Investigation, 2005, 115, 1644-1650.	8.2	72
24	Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood, 2004, 103, 2337-2342.	1.4	210
25	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. Journal of Leukocyte Biology, 2003, 74, 593-601.	3.3	17
26	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood, 2003, 101, 1962-1969.	1.4	139
27	The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood, 2003, 101, 1262-1269.	1.4	221
28	Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood, 2003, 102, 497-505.	1.4	142
29	Robust and Efficient Regulation of Transgene Expression in Vivo by Improved Tetracycline-Dependent Lentiviral Vectors. Molecular Therapy, 2002, 5, 252-261.	8.2	145
30	Effect of prolactin on natural killer and MHC-restricted cytotoxic cells. NeuroImmune Biology, 2002, , 205-218.	0.2	1
31	Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. European Journal of Immunology, 2002, 32, 1403.	2.9	235
32	Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood, 2001, 97, 2777-2783.	1.4	299
33	A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry, 2001, 45, 151-157.	1.8	95
34	Human CD38 and its ligand CD31 define a uniquelamina propriaT lymphocyte signaling pathway. FASEB Journal, 2001, 15, 580-582.	0.5	33
35	IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk. Journal of Immunology, 2001, 166, 3890-3899.	0.8	157
36	Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. International Journal of Cancer, 2000, 85, 124-130.	5.1	26

Massimo Geuna

#	Article	IF	CITATIONS
37	Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nature Genetics, 2000, 25, 217-222.	21.4	887
38	Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line. Journal of Neuroimmunology, 1997, 79, 12-21.	2.3	57
39	Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. , 1997, 172, 1-11.		62
40	Relationships between Proliferative Activity and Oncogene Expression in Human Breast Cancer. Annals of the New York Academy of Sciences, 1996, 784, 555-563.	3.8	1
41	DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Human Pathology, 1996, 27, 676-682.	2.0	32
42	p53 expression and proliferative activity predict survival in non-invasive thymomas. , 1996, 69, 180-183.		12
43	Long-term Survival of Thymoma Patients by Histologic Pattern and Proliferative Activity. American Journal of Surgical Pathology, 1995, 19, 918-926.	3.7	28
44	Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. Journal of Cellular Physiology, 1995, 163, 221-231.	4.1	60
45	Isochromosome 6p and deletion of 6q characterize two related cytogenetic clones in a patient with immunoblastic lymphoma. Cancer Genetics and Cytogenetics, 1995, 81, 179-181.	1.0	3
46	Biological Heterogeneity of Diffuse Mixed Small and Large Cell Non-Hodgkin's Lymphomas Assessed by DNA Flow Cytometry and Ki67. Leukemia and Lymphoma, 1995, 19, 467-472.	1.3	6
47	Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology, 1994, 28, 67-75.	2.0	43
48	Bâ€cell chronic lymphocytic leukaemia stage 0. An immunophenotypic study of 66 cases and comparison with B small cell lymphomas*. European Journal of Haematology, 1994, 52, 145-151.	2.2	2
49	Heterogeneous immunoglobulin gene rearrangement in a B-chronic lymphocytic leukemia progressing into non-Hodgkin lymphoma (richter syndrome). Cancer, 1993, 71, 359-363.	4.1	8
50	Distribution of interferon-Î <sup>3</sup> receptor in human tissues. European Journal of Immunology, 1992, 22, 2403-2412.	2.9	165
51	Modulation of extracellular matrix receptors (integrins) on human endothelial cells by cytokines. Exs, 1992, 61, 193-197.	1.4	6
52	In Vitro and In Vivo Comparison of the Activity of Human Lymphokine-Activated Killer (LAK) Cells and Adherent LAK Cells. Journal of Immunotherapy, 1991, 10, 189-199.	2.4	12
53	Immunophenotype of thymoma-associated lymphoid cell component of T-cell type. Vigiliae Christianae, 1990, 59, 297-304.	0.1	11
54	Cancer cells in effusions and increases in T-activated lymphocytes. European Journal of Cancer & Clinical Oncology, 1990, 26, 852.	0.7	0

#	Article	IF	CITATIONS
55	Identification of a new epitope of the 4F2/44D7 molecular complex present on sarcolemma and isolated cardiac fibers. European Journal of Immunology, 1989, 19, 1-8.	2.9	24
56	Relationship between structure and T-lymphocyte maturation in human thymomas. Vigiliae Christianae, 1986, 52, 389-402.	0.1	6